Dermatol. praxi. 2013;7(2):56-59

Diffuse hair thinning

MUDr.Renata Kučerová, Ph.D.
Klinika chorob pohlavních a kožních FN a LF UP Olomouc

Aetiopathogenetic aspects

Diffuse hair loss is a common condition and a cause of mental problems in affected women and men. An understanding of individual

types of hair loss is based on the knowledge of hair cycle physiology. Differential diagnosis involves a distinction of telogen effluvium

from anagen (or dystrophic anagen) effluvium as well as of androgenic alopecia that has a typical clinical presentation.

Keywords: telogen effluvium, dystrophic anagen effluvium, androgenic alopecia

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kučerová R. Diffuse hair thinning. Dermatol. praxi. 2013;7(2):56-59.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bartošová L, Jorda V, Šťáva Z. Choroby vlasů a ovlasené kůže. 1. vyd. Praha: Avicenum 1982: 56.
    2. Trüeb RM. Systematic approach to hair loss in women. Journal der Deutschen Dermatologischen Gesellschaft 2010. Go to original source... Go to PubMed...
    3. Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol 1993; 129: 356-363. Go to original source... Go to PubMed...
    4. Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol 1996; 35: 899-906. Go to original source... Go to PubMed...
    5. Guy WB, Edmundson WF. Diffuse cyclic hair loss in women. Arch Dermatol 1960; 81: 205-227. Go to original source... Go to PubMed...
    6. Kligman AM. Pathologic dynamics if human hair loss, I: telogen effluvium. Arch Dermatol 1961; 83: 175-198. Go to original source... Go to PubMed...
    7. Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg 2009; 28: 11-14. Go to original source... Go to PubMed...
    8. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol 2002; 27: 396-404. Go to original source... Go to PubMed...
    9. Bregy A, Trüeb RM. No association between serum ferritin levels > 10 microg/l and hair loss activity in women. Dermatology 2008; 217(1): 1-6. Go to original source... Go to PubMed...
    10. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 2003; 121: 985-988. Go to original source... Go to PubMed...
    11. Tosti A, Whiting D, Iorizzo M, Pazzaglia M, Misciali C, Vincenzi C, Micali G. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol 2008; 59: 64-67. Go to original source... Go to PubMed...
    12. Norwood OT. Male-pattern baldness. Classification and incidence. South Med J 1975; 68: 1359-1370. Go to original source... Go to PubMed...
    13. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001; 27: 53-54. Go to original source... Go to PubMed...
    14. King MW, Marchesini S. Steroid hormones and receptors. <http://www.med.unibs.it/~marchesi/sterhorm.html>: 2004: 11.
    15. Randall VA. The use of dermal papilla cells in studies of normal and abnormal hair follicle biology. Dermatol Clin 1996; 14: 585-584. Go to original source... Go to PubMed...
    16. Randall VA, Hibberts NA, Thornton MJ, Merrick AE, Hamada K, Kato S, Jenner TJ, de Oliveira I, Messenger AG. Do androgens influence hair growth by altering the paracrine factors secreted by dermal papilla cells? Eur J Dermatol 2001; 11: 315-320.
    17. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive patients with diffuse alopecia. J Am Acad Dermatol 1998; 19: 831-836. Go to original source... Go to PubMed...
    18. Cuscan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparsion of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61: 281-287. Go to original source... Go to PubMed...
    19. O´Driscoll JB, Mamtora H, Higginso J, Pollock A, Kane J, Anderson DC. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenetic alopetia. Clin Endocrinol 1994; 41: 231-236. Go to original source... Go to PubMed...
    20. Sawaya ME. Novel agents for treatment of alopecia. Semin Cutan Med Surg 1998; 177: 276-283. Go to original source... Go to PubMed...
    21. Cotsarelis G, Millar S. Towards a molecular understanding of hair loss and its treatment. Trends mol med 2001; 7: 293-301. Go to original source... Go to PubMed...
    22. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001; 116: 452-455. Go to original source... Go to PubMed...
    23. Jaworsky C, Kligman AM, Murphy GF. Characterisation of inflammatory infiltrates in male pattern alopecia: implication for pathogenesis. Br J Dermatol 1992; 127: 239-246. Go to original source... Go to PubMed...
    24. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 28: 755-763. Go to original source... Go to PubMed...
    25. Mahé YF, Michelet JF, Billoni N, Jarrousse F, Buan B, Commo S, Seint-leger D, Bernard BS. Androgenetic alopecia and microinflammation. Int J Dermatol 2000; 39: 576-584. Go to original source... Go to PubMed...
    26. Lavker RM, Miller S, Wilson C, Cotsarelis G, Wei ZG, Yang JS, Sun TT. Hair follicle stem cells: their location, role in hair cycle, and involvement in skin tumor formation. J Invest Dermatol 1993; 101: 16-26. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.